Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis

• Main Authors: Takeshi Nakahara (Author), Hiroyuki Murota (Author), Miyuki Matsukawa (Author), Hiroe Takeda (Author), Yilong Zhang (Author), Tomohiro Kondo (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe in phases 2 and 3 clinical trials in Japan. However, there are no head-to-head trials comparing the...